ASCO24 Updates: Dr. Yuichi Ozawa – Key Factors Affecting PFS in NSCLC Patients

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most prestigious conferences in the field of oncology. This year, the meeting took place from May 31 to June 4 in Chicago, Illinois. The event gathers oncologists, researchers, and healthcare professionals from around the world to discuss the latest advancements in cancer research, treatment, and patient care. Keynote sessions, research presentations, and panel discussions are typically part of the agenda, providing attendees with valuable insights into emerging trends and innovations in oncology.

This year, OncoDaily was at ASCO 2024 for the first time covering the meeting on-site. We had the pleasure of interviewing researchers who summarized the highlights of their work.

In this video, Dr. Yuichi Ozawa from Hamamatsu Medical Center, shares insights on ‘Comprehensive analysis of predictive factors for efficacy in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer, utilizing individual patient data from the Japan lung cancer society integrated clinical trial database: Is there room for further improvement?‘

My name is Yuichi Ozawa. I’m from Hamamatsu Medical Center in Japan, and I’m now presenting in this ASCO annual meeting about the comprehensive analysis for the locally advanced non-small lung cancer who received concurrent chemotherapy utilizing individual data from the Japan Lung Cancer Society integrated clinical trial databases. Actually, the Japan Lung Cancer Society made databases using the 1,200 data, and I analyzed using that.

The result is kind of interesting because we found that five factors are related with PFAS, person with survival. The most important one is the site of the lung cancer. I mean that the lung cancer originates at the upper lobes, so the shorter person with survival, better, longer person with survival than the lung cancer that originates from the lower lobes.

And more than that, we also found that the patients who show the pneumonitis, that’s more than grade 2, show shorter survival. And on the contrary, the esophagitis, more than grade 1, shows longer person with survival. That’s very depending on the adverse events, kind of adverse events.

And we also want to show the detailed profiles of the adverse events who received concurrent chemotherapy in the 1,200 patients. Actually, until now, we don’t know about the predictive factors of the locally advanced non-small lung cancer patients who received concurrent chemotherapy. And I think this is the first one who analyzed that using such many patients.

And even the adverse event profiles are, I think, very informative for all clinicians.

More videos and content from ASCO 2024 on OncoDaily.